Qarziba
Qarziba is an originator product from Medius AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 8'602.80 to CHF 8'602.80 depending on the pack; the patient co-payment is 10 per cent plus the deductible.
Core data
- Authorisation holder
- Medius AG
- ATC code
- L01FX06
- IT group
- 07.16.10 Cytostatica
- Active substances
- Dinutuximabum beta
- Preparation type
- Originator product
- On the SL since
- 01/03/2026
- Last price change
- 01/03/2026
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Inf Konz 20.25 mg/4.5 ml | 1 Fl | CHF 8'084.81 | CHF 8'602.80 | 01/06/2026 | A | 7680674630012 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
QARZIBA wird vergütet in Kombination mit Isotretinoin für die Behandlung von Hochrisiko-Neuroblastom bei pädiatrischen Patienten im Alter von 12 Monaten und älter, die zuvor eine Induktions-Chemotherapie erhalten und zumindest eine partielle Remission erreicht haben, gefolgt von myeloablativer Therapie und Stammzelltransplantation.
QARZIBA wird vergütet in Kombination mit Isotretinoin oder als Monotherapie für die Behandlung von rezidivierten oder refraktären Neuroblastomen mit oder ohne Residualerkrankung in der Anamnese bei pädiatrischen Patienten im Alter von 12 Monaten und älter, bei denen keine aktiv progrediente Erkrankung vorliegt. Vor der Behandlung eines rezidivierten Neuroblastoms sind jegliche aktive progredienten Erkrankungen mithilfe anderer geeigneter Massnahmen zu stabilisieren.
Für die Kombination mit Isotretinoin werden nur Präparate, welche in der SL gelisteten sind, vergütet.
FAQ
Is Qarziba covered by Swiss health insurance?
Yes, but only under conditions. Qarziba is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Qarziba cost in Switzerland?
The public price is the maximum price set by the FOPH and for Qarziba ranges from CHF 8'602.80 to CHF 8'602.80 per pack. The ex-factory price ranges from CHF 8'084.81 to CHF 8'084.81. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages